ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1642

CD25+CD39+ Regulatory T Cells Are Enriched At The Site Of Inflammation Of Patients With Rheumatoid Arthritis and Impaired In Suppressing IL-17A Secretion

Jessica Herrath1, Karine Chemin2, Inka Albrecht1, Anca Catrina2 and Vivianne Malmström3, 1Department of Medicine, Solna, Unit of Rheumatology, Karolinska University Hospital, Department of Medicine, Solna, Unit of Rheumatology, Stockholm, Sweden, 2Department of Medicine, Solna, Unit of Rheumatology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 3Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: T-Regulatory Cells and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: T-cell Biology in Autoimmune Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Regulatory T cells (Tregs) are important for the maintenance of self-tolerance and are implicated in the origin of autoimmunity. Despite enrichment of Tregs in joints of rheumatoid arthritis (RA) patients, local inflammation persists and becomes chronic. Recently, CD39 expression has been described on FOXP3+ Tregs and suggested to be a novel mechanism of Treg suppression by producing anti-inflammatory adenosine together with CD73. Interestingly the capacity of CD39+ Treg to suppress Th17 responses is impaired in multiple sclerosis. Whether this defect is a general feature found in autoimmune diseases is currently unknown. In this study, we first aimed to better characterize the CD39+ Treg compartment in blood and synovial fluids from RA patients. We then further addressed their capacity in suppressing T effector cell responses, especially Th17 responses.

Methods:

Multi-parameter flow cytometry was used to assess the ex vivo frequencies of FOXP3+CD39+ and FOXP3+CD39- Tregs in blood of healthy controls (n=11) and RA patients (n=15) as well as at the site of inflammation of RA (n=15) and spondylarthropathy patients (n=10). In addition, the differential suppressive capacity of synovial CD39+ and CD39- Tregs was investigated by conventional co-culture systems (n=6). Proliferation and cytokine secretion was measured by thymidine incorporation and luminex, respectively.

Results:

FOXP3+CD39+ Tregs were enriched at the site of inflammation (p=0.0007) whereas synovial FOXP3+CD73+ Tregs were reduced compared to the circulation (p<0.001). The same pattern for CD39 and CD73 expression was also seen for the total population of synovial CD4+ T cells, (p<0.0001). Furthermore, synovial CD25+CD39+ Tregs were able to suppress proliferation of T effector cells (p=0.0313) in contrast to their CD39- counterparts that proliferated instead (p=0.026). Finally, cytokine suppression was exerted by the CD25+CD39+ Treg subset (and not by CD39-) for many cytokines but not for IL-17A.

Conclusion:

Our data suggest that FOXP3+CD39- and FOXP3+CD39+ Tregs are distinct subsets with different functions as exemplified by synovial CD39- T cells that proliferate in vitro and secrete pro-inflammatory cytokines instead of suppressing them. CD39- Tregs could represent plastic Tregs that converted to IL-17 producers under inflammatory conditions. Furthermore, we demonstrate that, in synovial fluid, CD39+ Treg are impaired in suppressing IL-17A secretion, a cytokine that may contribute to disease pathogenesis. This finding could partly explain why accumulation of Tregs is seen at the site of inflammation without facilitating remission.


Disclosure:

J. Herrath,
None;

K. Chemin,
None;

I. Albrecht,
None;

A. Catrina,
None;

V. Malmström,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cd25cd39-regulatory-t-cells-are-enriched-at-the-site-of-inflammation-of-patients-with-rheumatoid-arthritis-and-impaired-in-suppressing-il-17a-secretion/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology